Cargando…

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosnowska, Bożena, Adach, Weronika, Surma, Stanisław, Rosenson, Robert S., Banach, Maciej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821629/ https://www.ncbi.nlm.nih.gov/pubmed/36614969 http://dx.doi.org/10.3390/jcm12010168

Ejemplares similares

Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy
por: Sosnowska, Bożena, et al.
Publicado: (2022)

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?
por: Surma, Stanisław, et al.
Publicado: (2021)

OR24-02 Case Series Of Canadian Patients With Homozygous Familial Hypercholesterolemia Treated With ANGPTL3 Inhibitor Evinacumab
por: Shamsudeen, Isabel, et al.
Publicado: (2023)

Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
por: Rosenson, Robert S., et al.
Publicado: (2023)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

2023: The year in cardiovascular disease – the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?
por: Banach, Maciej, et al.
Publicado: (2023)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
por: Chen, Pei-Yi, et al.
Publicado: (2021)

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
por: Banach, Maciej, et al.
Publicado: (2022)

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies
por: Surma, Stanisław, et al.
Publicado: (2021)

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023)

COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
por: Surma, Stanisław, et al.
Publicado: (2021)

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
por: Rosenson, Robert S., et al.
Publicado: (2023)

Dietary salt intake and atherosclerosis: an area not fully explored
por: Banach, Maciej, et al.
Publicado: (2023)

A look to the past – what has had the biggest impact on lipids in the last four decades? A personal perspective
por: Banach, Maciej, et al.
Publicado: (2023)

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Fukami, Hirotaka, et al.
Publicado: (2021)

Menopause and women’s cardiovascular health: is it really an obvious relationship?
por: Ryczkowska, Kamila, et al.
Publicado: (2022)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Nutrition, Nutraceuticals and Bioactive Compounds in the Prevention and Fight against Inflammation
por: Surma, Stanisław, et al.
Publicado: (2023)

Associations of Betatrophin/ANGPTL8 with Septic Dyslipidemia in Human Peritonitis: An Explorative Analysis
por: Horn, Paul, et al.
Publicado: (2022)

Contemporary Management of Dyslipidemia
por: Ferraro, Richard A., et al.
Publicado: (2022)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
por: Kosmas, Constantine E, et al.
Publicado: (2022)

Malignancy-Associated Dyslipidemia
por: Bielecka-Dąbrowa, Agata, et al.
Publicado: (2011)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Circulating Angptl3 and Angptl8 Are Increased in Patients with Hypothyroidism
por: Yang, Longyan, et al.
Publicado: (2019)

Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment
por: Valiakou, Vaia, et al.
Publicado: (2021)

Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice
por: Pouwer, Marianne G., et al.
Publicado: (2020)

Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4
por: Landfors, Fredrik, et al.
Publicado: (2022)

The role of ANGPTL3 in controlling lipoprotein metabolism
por: Tikka, Anna, et al.
Publicado: (2016)

Knowledge of Primary Care Patients Living in the Urban Areas about Risk Factors of Arterial Hypertension
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
por: Stefanutti, Claudia, et al.
Publicado: (2022)

Serum ANGPTL8 and ANGPTL3 as Predictors of Triglyceride Elevation in Adult Women
por: Stefanska, Anna, et al.
Publicado: (2022)

ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
por: Chi, Xun, et al.
Publicado: (2017)

Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?
por: Surma, Stanisław, et al.
Publicado: (2022)

ANGPTL3 as therapeutic target
por: Kersten, Sander
Publicado: (2021)

ANGPTL4 gene E40K variation protects against obesity‐associated dyslipidemia in participants with obesity
por: Bailetti, D., et al.
Publicado: (2018)

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
por: Biterova, Ekaterina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j0p90je39v67hgacs5uss6icrr